Product IntroductionBioactivity英文名:
Naxitamab描述: Naxitamab (Hu3F8) 是一种针对二氮冈糖苷 GD2 (hu3F8)的人源化单克隆抗体。Naxitamab 具有抗肿瘤活性,可用于研究神经母细胞瘤、骨肉瘤和其他 GD2 阳性癌症。
体外活性: Naxitamab (Hu3F8; 72 h) exhibits cytotoxicity against the neuroblastoma cell line LAN-1, with an EC50 value of 5.1 μg/mL[1].Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) demonstrates antibody-dependent cell-mediated cytotoxic effects (ADCC)[1].
体内活性: 在裸鼠携带LAN-1异种移植瘤模型中,Naxitamab(Hu3F8;100 mg/kg;静脉注射;每周两次,持续4周)可抑制神经母细胞瘤异种移植瘤的生长[1]。
存储条件: store at low temperaturestore at -80°C
关键字:
Naxitamab